

113TH CONGRESS  
2D SESSION

# H. R. 4472

To provide for the establishment of a grant program to support United States-Israeli cooperation for neuroscience-related research, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

APRIL 10, 2014

Mr. FATTAH introduced the following bill; which was referred to the  
Committee on Energy and Commerce

---

## A BILL

To provide for the establishment of a grant program to support United States-Israeli cooperation for neuroscience-related research, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “US–Israel Global Neu-  
5 roscience Partnership Act of 2014”.

6 **SEC. 2. FINDINGS.**

7 Congress finds that—

1           (1) it is in the highest national security inter-  
2           ests of the United States to develop neuroscience-re-  
3           lated research and neurotechnology;

4           (2) the State of Israel is a steadfast ally of the  
5           United States;

6           (3) the special relationship between the United  
7           States and Israel is manifested in a variety of coop-  
8           erative scientific research and development pro-  
9           grams, such as—

10                   (A) the United States-Israel Binational  
11                   Science Foundation; and

12                   (B) the United States-Israel Binational In-  
13                   dustrial Research and Development Founda-  
14                   tion;

15           (4) those programs have made possible many  
16           scientific, technological, and commercial break-  
17           throughs in the fields of life sciences, medicine, bio-  
18           engineering, agriculture, biotechnology, communica-  
19           tions, and others;

20           (5) in December 2011 the Office of Science and  
21           Technology Policy was directed by Congress to es-  
22           tablish an Interagency Working Group on Neuro-  
23           science which was chartered on June 20, 2012, is  
24           housed at the White House, and is currently con-  
25           vening representatives across the Federal Govern-

1       ment to make recommendations about the future of  
2       neuroscience research;

3               (6) Israeli scientists and engineers are at the  
4       forefront of research and development in the field of  
5       neuroscience;

6               (7) Israel Brain Technologies is a nonprofit or-  
7       ganization whose mission is to turn Israel into a  
8       global brain technology and research leader by—

9                       (A) supporting applied brain research;

10                      (B) accelerating brain technology develop-  
11       ment;

12                      (C) creating and fostering a community  
13       around neurotechnology; and

14                      (D) attracting key stakeholders to partner  
15       and support brain technology in Israel; and

16               (8) enhanced cooperation between the United  
17       States and Israel for the purpose of research and de-  
18       velopment of neuroscience would be in the national  
19       interests of both countries.

20   **SEC. 3. GRANTS FOR NEUROSCIENCE-RELATED RESEARCH.**

21       (a) **AUTHORITY.**—The Secretary, acting through the  
22       Director of the National Institutes of Health, in consulta-  
23       tion with the BIRD or BSF, shall award grants to eligible  
24       entities for neuroscience-related research.

25       (b) **APPLICATION.**—

1           (1) SUBMISSION OF APPLICATIONS.—To receive  
2           a grant under this section, an eligible entity shall  
3           submit an application to the Secretary containing  
4           such information and assurances as the Secretary, in  
5           consultation with the BIRD or BSF, may require.

6           (2) SELECTION OF ELIGIBLE ENTITIES.—The  
7           Secretary, in consultation with the Directors of the  
8           BIRD and BSF, may review any application sub-  
9           mitted by any eligible entity and select any eligible  
10          entity meeting criteria established by the Secretary,  
11          in consultation with the Advisory Board, for a grant  
12          under this section.

13          (c) AMOUNT OF GRANT.—The amount of each grant  
14          awarded for a fiscal year under this section shall be deter-  
15          mined by the Secretary, in consultation with the BIRD  
16          or BSF.

17          (d) RECOUPMENT.—

18               (1) IN GENERAL.—Not later than 180 days  
19               after the date of enactment of this Act, the Sec-  
20               retary shall establish procedures and criteria for  
21               recoupment in connection with any eligible project  
22               carried out by an eligible entity that receives a grant  
23               under this section, which has led to the development  
24               of a product or process which is marketed or used.

25               (2) AMOUNT REQUIRED.—

1           (A) Except as provided in subparagraph  
2           (B), such recoupment shall be required as a  
3           condition for award and be proportional to the  
4           Federal share of the costs of such project, and  
5           shall be derived from the proceeds of royalties  
6           or licensing fees received in connection with  
7           such product or process.

8           (B) In the case where a product or process  
9           is used by the recipient of a grant under this  
10          section for the production and sale of its own  
11          products or processes, the recoupment shall  
12          consist of a payment equivalent to the payment  
13          which would be made under subparagraph (A).

14         (3) WAIVER.—The Secretary may at any time  
15         waive or defer all or some of the recoupment re-  
16         quirements of this subsection as necessary, depend-  
17         ing on—

18                 (A) the commercial competitiveness of the  
19                 entity or entities developing or using the prod-  
20                 uct or process;

21                 (B) the profitability of the project; and

22                 (C) the commercial viability of the product  
23                 or process utilized.

1 (e) PRIVATE FUNDS.—The Secretary may accept  
2 contributions of funds from private sources to carry out  
3 this Act.

4 (f) REPORT.—Not later than 180 days after receiving  
5 a grant under this section, each recipient shall submit a  
6 report to the Secretary—

7 (1) documenting how the recipient used the  
8 grant funds; and

9 (2) evaluating the level of success of each  
10 project funded by the grant.

11 **SEC. 4. INTERNATIONAL NEUROSCIENCE-RELATED RE-**  
12 **SEARCH ADVISORY BOARD.**

13 (a) ESTABLISHMENT.—There is established in the  
14 National Institutes of Health an International Neuro-  
15 science-Related Research Advisory Board.

16 (b) DUTIES.—The Advisory Board shall advise the  
17 Secretary on—

18 (1) criteria for the recipients of grants awarded  
19 under section 3(a);

20 (2) the total amount of grant money to be  
21 awarded to all grantees selected by the Secretary, in  
22 consultation with the BIRD; and

23 (3) the total amount of grant money to be  
24 awarded to all grantees selected by the Secretary, in  
25 consultation with the BSF, for each fiscal year.

1 (c) MEMBERSHIP.—

2 (1) COMPOSITION.—The Advisory Board shall  
3 be composed of—

4 (A) 1 member appointed by the Director of  
5 the National Science Foundation;

6 (B) 1 member appointed by the Director of  
7 the National Institutes of Health;

8 (C) 1 member appointed by the Director of  
9 the National Institute of Standards and Tech-  
10 nology; and

11 (D) in addition to the member appointed  
12 under subparagraph (B), 3 members who shall  
13 be Israeli citizens, appointed by the Director of  
14 the National Institutes of Health after con-  
15 sultation with appropriate officials in the Israeli  
16 Government.

17 (2) DEADLINE FOR APPOINTMENTS.—The ini-  
18 tial appointments under paragraph (1) shall be  
19 made not later than 60 days after the date of enact-  
20 ment of this Act.

21 (3) TERM.—Each member of the Advisory  
22 Board shall be appointed for a term of 4 years.

23 (4) VACANCIES.—A vacancy on the Advisory  
24 Board shall be filled in the manner in which the  
25 original appointment was made.

1 (5) BASIC PAY.—

2 (A) COMPENSATION.—A member of the  
3 Advisory Board shall serve without pay.

4 (B) TRAVEL EXPENSES.—Each member of  
5 the Advisory Board shall receive travel ex-  
6 penses, including per diem in lieu of subsist-  
7 ence, in accordance with applicable provisions of  
8 subchapter I of chapter 57 of title 5, United  
9 States Code.

10 (6) QUORUM.—Three members of the Advisory  
11 Board shall constitute a quorum.

12 (7) CHAIRPERSON.—The Chairperson of the  
13 Advisory Board shall be designated by the Director  
14 of the National Institutes of Health from among the  
15 members appointed by the Director at the time of  
16 the appointment.

17 (8) MEETINGS.—The Advisory Board shall  
18 meet at least once annually at the call of the Chair-  
19 person.

20 (d) TERMINATION.—Section 14(a)(2)(B) of the Fed-  
21 eral Advisory Committee Act (5 U.S.C. App.) shall not  
22 apply to the Advisory Board.

23 **SEC. 5. DEFINITIONS.**

24 In this Act:



1           (1) ADVISORY BOARD.—The term “Advisory  
2       Board” means the International Neuroscience-Related Research Advisory Board established by section 4(a).

5           (2) BIRD.—The term “BIRD” means the  
6       Israel-United States Binational Industrial Research  
7       and Development Foundation.

8           (3) BSF.—The term “BSF” means the United  
9       States-Israel Binational Science Foundation.

10          (4) ELIGIBLE ENTITY.—The term “eligible entity” means a joint venture comprised of both Israeli and United States private business entities or a joint venture comprised of both Israeli academic persons (who reside and work in Israel) and United States academic persons, that—

16                   (A) carries out an eligible project; and

17                   (B) is selected by the Secretary, in consultation with the BIRD or BSF, using the criteria established by the Secretary, in consultation with the Advisory Board.

21          (5) ELIGIBLE PROJECT.—The term “eligible project” means a project to encourage cooperation between the United States and Israel on neuroscience-related research.

1           (6) SECRETARY.—The term “Secretary” means  
2       the Secretary of Health and Human Services.

3   **SEC. 6. TERMINATION.**

4       The grant program authorized under section 3 and  
5   the Advisory Board shall terminate upon the expiration  
6   of the 7-year period which begins on the date of the enact-  
7   ment of this Act.

8   **SEC. 7. AUTHORIZATION OF APPROPRIATIONS.**

9       The Secretary is authorized to expend not more than  
10   \$20,000,000 to carry out this Act for each of fiscal years  
11   2014 through 2020.

○